Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | AKT2 | P31751 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | LDHA | P00338 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9585821 | 0.81 | — | — | |
| SCHEMBL1895601 | 0.80 | CYP2A6 (0.52) | RAB9AMAPK1METAP2NPC1SMN1; SMN2 | |
| SCHEMBL1896111 | 0.77 | HSD17B1 (0.65) | METAP2HDAC6 | |
| SCHEMBL9437048 | 0.76 | — | — | |
| SCHEMBL1893871 | 0.75 | KDM4E (0.56) | RAB9AMAPK1METAP2HPGDSNPC1 | |
| SCHEMBL970459 | 0.75 | DYRK1A (0.51) | SMN1; SMN2NPY5RMAPT | |
| SCHEMBL1896163 | 0.75 | PDGFRB (0.50) | ALDH1A1GLAMAPT | |
| SCHEMBL10462380 | 0.75 | METAP2 (0.46) | RAB9AMAPK1METAP2NPC1SMN1; SMN2 | |
| SCHEMBL10462004 | 0.74 | SMN1; SMN2 (0.44) | RAB9AMEN1KMT2AMAPK1NPC1 | |
| SCHEMBL1304066 | 0.73 | RAB9A (0.52) | RAB9AMEN1KMT2AMAPK1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937669-B9 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA NV (BE) | 2012-07-18 | — | — | EP | claimed |
| EP-1937669-B1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-01 | — | — | EP | claimed |
| CN-101296925-A | Novel benzopyran derivatives as potassium channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2008-10-29 | — | — | CN | claimed |
| EP-1937669-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-02 | — | — | EP | claimed |
| WO-2007027959-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-08 | — | — | WO | claimed |
| US-20070049556-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-01 | — | — | US | claimed |
| US-5624937-A | TREATMENT OF ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1997-04-29 | — | — | US | claimed |
| JP-H08505880-A | — | — | 1996-06-25 | — | — | JP | claimed |
| US-20230365556-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| CN-109563126-B | Proteasome inhibitors | 马克斯-普朗克科学促进学会 | 2023-06-16 | — | — | CN | disclosed |
| US-11673887-B2 | N-acyl amino acid compounds and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| EP-3464321-B1 | PROTEASOME INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2023-01-25 | — | — | EP | disclosed |
| US-11345724-B2 | Proteasome inhibitors | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-05-31 | — | — | US | disclosed |
| US-20210024516-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2021-01-28 | — | — | US | disclosed |
| US-6326375-B1 | CONTAINING AN UREA GROUP | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2001-12-04 | — | — | US | disclosed |
| WO-2001014376-A1 | NOVEL SPIRO COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2001-03-01 | — | — | WO | disclosed |
| US-5814646-A | TREATING THE PROGRESSION OF ALZHEIMER'S DISEASE, BRAIN DISORDERS | ELI LILLY AND COMPANY (US) | 1998-09-29 | — | — | US | disclosed |
| US-5624937-A | TREATMENT OF ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1997-04-29 | — | — | US | disclosed |
| US-5202321-A | Antihistamine, antiallergens, antiinflammatory agents | MERCK FROSST CANADA, INC. (CA) | 1993-04-13 | — | — | US | disclosed |
| EP-0518426-A1 | Thiopyrano (2,3,4-c,d) indoles as inhibitors of leukotriene biosynthesis | MERCK FROSST CANADA INC. (CA) | 1992-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673887-B2 | N-acyl amino acid compounds and methods of use | ITGA1, ITGB1, ITGAL | RAB9A 531/4885MEN1 2401/4885KMT2A 1313/4885 |
| US-20210024516-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | ITGA1, ITGB1, ITGAL | RAB9A 531/4885MEN1 2401/4885KMT2A 1313/4885 |
| US-20070049556-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | KCNJ2, KCNN1, KCNN3 | RAB9A 2819/4885MEN1 3815/4885KMT2A 1443/4885 |
| US-11345724-B2 | Proteasome inhibitors | PSMB1, PSMB2, PSMB5 | RAB9A 3148/4885MEN1 3000/4885KMT2A 642/4885 |
| US-20230365556-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | ITGA1, ITGB1, ITGAL | RAB9A 531/4885MEN1 2401/4885KMT2A 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.